 | • レポートコード：D0GIR-02495 • 出版社/出版日：GlobalInfoResearch / 2020年9月30日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、126ページ • 納品方法：Eメール • 産業分類：医療、製薬、バイオ |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、非黒色腫皮膚がんの世界市場を広く調査・分析し、今後の市場展望をまとめております。非黒色腫皮膚がんの種類別市場規模（化学療法、放射線療法、光線力学療法）、用途別市場規模（病院、クリニック、外来手術センター、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Boehringer Ingelheim、Sun Pharmaceutical、Roche、Bristol-Myers Squibb、Mylan、Eli Lilly、Elekta、Novartis、Merck、Almirall、Ion Beam Applications、Varian Medical Systems、Accuray、Sensus Healthcare、iCAD ・地域別グローバル市場分析 2015年-2020年 ・非黒色腫皮膚がんの北米市場（アメリカ、カナダ、メキシコ） ・非黒色腫皮膚がんのヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・非黒色腫皮膚がんのアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・非黒色腫皮膚がんの南米市場（ブラジル、アルゼンチン） ・非黒色腫皮膚がんの中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：化学療法、放射線療法、光線力学療法 ・用途別分析：病院、クリニック、外来手術センター、その他 ・地域別市場規模予測 2021年-2025年 ・調査の結果・結論 |
Market Overview
The global Non-Melanoma Skin Cancer market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
The Non-Melanoma Skin Cancer market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Non-Melanoma Skin Cancer market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Non-Melanoma Skin Cancer market has been segmented into:
Chemotherapy
Radiation Therapy
Photodynamic Therapy
By Application, Non-Melanoma Skin Cancer has been segmented into:
Hospitals
Clinics
Ambulatory Surgical Centers
Others
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Non-Melanoma Skin Cancer market presented in the report. This section sheds light on the sales growth of different regional and country-level Non-Melanoma Skin Cancer markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Non-Melanoma Skin Cancer market.
The report offers in-depth assessment of the growth and other aspects of the Non-Melanoma Skin Cancer market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and Non-Melanoma Skin Cancer Market Share Analysis
Non-Melanoma Skin Cancer competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Non-Melanoma Skin Cancer sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Non-Melanoma Skin Cancer sales, revenue and market share for each player covered in this report.
The major players covered in Non-Melanoma Skin Cancer are:
Boehringer Ingelheim
Sun Pharmaceutical
Roche
Bristol-Myers Squibb
Mylan
Eli Lilly
Elekta
Novartis
Merck
Almirall
Ion Beam Applications
Varian Medical Systems
Accuray
Sensus Healthcare
iCAD
Table of Contents
1 Non-Melanoma Skin Cancer Market Overview
1.1 Product Overview and Scope of Non-Melanoma Skin Cancer
1.2 Classification of Non-Melanoma Skin Cancer by Type
1.2.1 Global Non-Melanoma Skin Cancer Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Non-Melanoma Skin Cancer Revenue Market Share by Type in 2019
1.2.3 Chemotherapy
1.2.4 Radiation Therapy
1.2.5 Photodynamic Therapy
1.3 Global Non-Melanoma Skin Cancer Market by Application
1.3.1 Overview: Global Non-Melanoma Skin Cancer Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Centers
1.3.5 Others
1.4 Global Non-Melanoma Skin Cancer Market by Regions
1.4.1 Global Non-Melanoma Skin Cancer Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Non-Melanoma Skin Cancer (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Non-Melanoma Skin Cancer Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Non-Melanoma Skin Cancer Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Non-Melanoma Skin Cancer Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Non-Melanoma Skin Cancer Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Non-Melanoma Skin Cancer Status and Prospect (2015-2025)
2 Company Profiles
2.1 Boehringer Ingelheim
2.1.1 Boehringer Ingelheim Details
2.1.2 Boehringer Ingelheim Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Boehringer Ingelheim SWOT Analysis
2.1.4 Boehringer Ingelheim Product and Services
2.1.5 Boehringer Ingelheim Non-Melanoma Skin Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.2 Sun Pharmaceutical
2.2.1 Sun Pharmaceutical Details
2.2.2 Sun Pharmaceutical Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Sun Pharmaceutical SWOT Analysis
2.2.4 Sun Pharmaceutical Product and Services
2.2.5 Sun Pharmaceutical Non-Melanoma Skin Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.3 Roche
2.3.1 Roche Details
2.3.2 Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Roche SWOT Analysis
2.3.4 Roche Product and Services
2.3.5 Roche Non-Melanoma Skin Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.4 Bristol-Myers Squibb
2.4.1 Bristol-Myers Squibb Details
2.4.2 Bristol-Myers Squibb Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Bristol-Myers Squibb SWOT Analysis
2.4.4 Bristol-Myers Squibb Product and Services
2.4.5 Bristol-Myers Squibb Non-Melanoma Skin Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.5 Mylan
2.5.1 Mylan Details
2.5.2 Mylan Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Mylan SWOT Analysis
2.5.4 Mylan Product and Services
2.5.5 Mylan Non-Melanoma Skin Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.6 Eli Lilly
2.6.1 Eli Lilly Details
2.6.2 Eli Lilly Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Eli Lilly SWOT Analysis
2.6.4 Eli Lilly Product and Services
2.6.5 Eli Lilly Non-Melanoma Skin Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.7 Elekta
2.7.1 Elekta Details
2.7.2 Elekta Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Elekta SWOT Analysis
2.7.4 Elekta Product and Services
2.7.5 Elekta Non-Melanoma Skin Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.8 Novartis
2.8.1 Novartis Details
2.8.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Novartis SWOT Analysis
2.8.4 Novartis Product and Services
2.8.5 Novartis Non-Melanoma Skin Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.9 Merck
2.9.1 Merck Details
2.9.2 Merck Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Merck SWOT Analysis
2.9.4 Merck Product and Services
2.9.5 Merck Non-Melanoma Skin Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.10 Almirall
2.10.1 Almirall Details
2.10.2 Almirall Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Almirall SWOT Analysis
2.10.4 Almirall Product and Services
2.10.5 Almirall Non-Melanoma Skin Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.11 Ion Beam Applications
2.11.1 Ion Beam Applications Details
2.11.2 Ion Beam Applications Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Ion Beam Applications SWOT Analysis
2.11.4 Ion Beam Applications Product and Services
2.11.5 Ion Beam Applications Non-Melanoma Skin Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.12 Varian Medical Systems
2.12.1 Varian Medical Systems Details
2.12.2 Varian Medical Systems Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 Varian Medical Systems SWOT Analysis
2.12.4 Varian Medical Systems Product and Services
2.12.5 Varian Medical Systems Non-Melanoma Skin Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.13 Accuray
2.13.1 Accuray Details
2.13.2 Accuray Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 Accuray SWOT Analysis
2.13.4 Accuray Product and Services
2.13.5 Accuray Non-Melanoma Skin Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.14 Sensus Healthcare
2.14.1 Sensus Healthcare Details
2.14.2 Sensus Healthcare Major Business and Total Revenue (Financial Highlights) Analysis
2.14.3 Sensus Healthcare SWOT Analysis
2.14.4 Sensus Healthcare Product and Services
2.14.5 Sensus Healthcare Non-Melanoma Skin Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.15 iCAD
2.15.1 iCAD Details
2.15.2 iCAD Major Business and Total Revenue (Financial Highlights) Analysis
2.15.3 iCAD SWOT Analysis
2.15.4 iCAD Product and Services
2.15.5 iCAD Non-Melanoma Skin Cancer Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Non-Melanoma Skin Cancer Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Non-Melanoma Skin Cancer Players Market Share
3.2.2 Top 10 Non-Melanoma Skin Cancer Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Non-Melanoma Skin Cancer Revenue and Market Share by Regions
4.2 North America Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
4.3 Europe Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
4.5 South America Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
5 North America Non-Melanoma Skin Cancer Revenue by Countries
5.1 North America Non-Melanoma Skin Cancer Revenue by Countries (2015-2020)
5.2 USA Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
5.3 Canada Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
5.4 Mexico Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
6 Europe Non-Melanoma Skin Cancer Revenue by Countries
6.1 Europe Non-Melanoma Skin Cancer Revenue by Countries (2015-2020)
6.2 Germany Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
6.3 UK Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
6.4 France Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
6.5 Russia Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
6.6 Italy Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Non-Melanoma Skin Cancer Revenue by Countries
7.1 Asia-Pacific Non-Melanoma Skin Cancer Revenue by Countries (2015-2020)
7.2 China Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
7.3 Japan Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
7.4 Korea Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
7.5 India Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
8 South America Non-Melanoma Skin Cancer Revenue by Countries
8.1 South America Non-Melanoma Skin Cancer Revenue by Countries (2015-2020)
8.2 Brazil Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
8.3 Argentina Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Non-Melanoma Skin Cancer by Countries
9.1 Middle East & Africa Non-Melanoma Skin Cancer Revenue by Countries (2015-2020)
9.2 Saudi Arabia Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
9.3 UAE Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
9.4 Egypt Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
9.5 South Africa Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Non-Melanoma Skin Cancer Revenue and Market Share by Type (2015-2020)
10.2 Global Non-Melanoma Skin Cancer Market Forecast by Type (2019-2024)
10.3 Chemotherapy Revenue Growth Rate (2015-2025)
10.4 Radiation Therapy Revenue Growth Rate (2015-2025)
10.5 Photodynamic Therapy Revenue Growth Rate (2015-2025)
11 Global Non-Melanoma Skin Cancer Market Segment by Application
11.1 Global Non-Melanoma Skin Cancer Revenue Market Share by Application (2015-2020)
11.2 Non-Melanoma Skin Cancer Market Forecast by Application (2019-2024)
11.3 Hospitals Revenue Growth (2015-2020)
11.4 Clinics Revenue Growth (2015-2020)
11.5 Ambulatory Surgical Centers Revenue Growth (2015-2020)
11.6 Others Revenue Growth (2015-2020)
12 Global Non-Melanoma Skin Cancer Market Size Forecast (2021-2025)
12.1 Global Non-Melanoma Skin Cancer Market Size Forecast (2021-2025)
12.2 Global Non-Melanoma Skin Cancer Market Forecast by Regions (2021-2025)
12.3 North America Non-Melanoma Skin Cancer Revenue Market Forecast (2021-2025)
12.4 Europe Non-Melanoma Skin Cancer Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Non-Melanoma Skin Cancer Revenue Market Forecast (2021-2025)
12.6 South America Non-Melanoma Skin Cancer Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Non-Melanoma Skin Cancer Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Table 1. Global Non-Melanoma Skin Cancer Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Non-Melanoma Skin Cancer by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Non-Melanoma Skin Cancer Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Non-Melanoma Skin Cancer Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Boehringer Ingelheim Corporate Information, Location and Competitors
Table 6. Boehringer Ingelheim Non-Melanoma Skin Cancer Major Business
Table 7. Boehringer Ingelheim Non-Melanoma Skin Cancer Total Revenue (USD Million) (2017-2018)
Table 8. Boehringer Ingelheim SWOT Analysis
Table 9. Boehringer Ingelheim Non-Melanoma Skin Cancer Product and Solutions
Table 10. Boehringer Ingelheim Non-Melanoma Skin Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Sun Pharmaceutical Corporate Information, Location and Competitors
Table 12. Sun Pharmaceutical Non-Melanoma Skin Cancer Major Business
Table 13. Sun Pharmaceutical Non-Melanoma Skin Cancer Total Revenue (USD Million) (2018-2019)
Table 14. Sun Pharmaceutical SWOT Analysis
Table 15. Sun Pharmaceutical Non-Melanoma Skin Cancer Product and Solutions
Table 16. Sun Pharmaceutical Non-Melanoma Skin Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Roche Corporate Information, Location and Competitors
Table 18. Roche Non-Melanoma Skin Cancer Major Business
Table 19. Roche Non-Melanoma Skin Cancer Total Revenue (USD Million) (2017-2018)
Table 20. Roche SWOT Analysis
Table 21. Roche Non-Melanoma Skin Cancer Product and Solutions
Table 22. Roche Non-Melanoma Skin Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Bristol-Myers Squibb Corporate Information, Location and Competitors
Table 24. Bristol-Myers Squibb Non-Melanoma Skin Cancer Major Business
Table 25. Bristol-Myers Squibb Non-Melanoma Skin Cancer Total Revenue (USD Million) (2017-2018)
Table 26. Bristol-Myers Squibb SWOT Analysis
Table 27. Bristol-Myers Squibb Non-Melanoma Skin Cancer Product and Solutions
Table 28. Bristol-Myers Squibb Non-Melanoma Skin Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Mylan Corporate Information, Location and Competitors
Table 30. Mylan Non-Melanoma Skin Cancer Major Business
Table 31. Mylan Non-Melanoma Skin Cancer Total Revenue (USD Million) (2017-2018)
Table 32. Mylan SWOT Analysis
Table 33. Mylan Non-Melanoma Skin Cancer Product and Solutions
Table 34. Mylan Non-Melanoma Skin Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Eli Lilly Corporate Information, Location and Competitors
Table 36. Eli Lilly Non-Melanoma Skin Cancer Major Business
Table 37. Eli Lilly Non-Melanoma Skin Cancer Total Revenue (USD Million) (2017-2018)
Table 38. Eli Lilly SWOT Analysis
Table 39. Eli Lilly Non-Melanoma Skin Cancer Product and Solutions
Table 40. Eli Lilly Non-Melanoma Skin Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. Elekta Corporate Information, Location and Competitors
Table 42. Elekta Non-Melanoma Skin Cancer Major Business
Table 43. Elekta Non-Melanoma Skin Cancer Total Revenue (USD Million) (2017-2018)
Table 44. Elekta SWOT Analysis
Table 45. Elekta Non-Melanoma Skin Cancer Product and Solutions
Table 46. Elekta Non-Melanoma Skin Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. Novartis Corporate Information, Location and Competitors
Table 48. Novartis Non-Melanoma Skin Cancer Major Business
Table 49. Novartis Non-Melanoma Skin Cancer Total Revenue (USD Million) (2017-2018)
Table 50. Novartis SWOT Analysis
Table 51. Novartis Non-Melanoma Skin Cancer Product and Solutions
Table 52. Novartis Non-Melanoma Skin Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. Merck Corporate Information, Location and Competitors
Table 54. Merck Non-Melanoma Skin Cancer Major Business
Table 55. Merck Non-Melanoma Skin Cancer Total Revenue (USD Million) (2017-2018)
Table 56. Merck SWOT Analysis
Table 57. Merck Non-Melanoma Skin Cancer Product and Solutions
Table 58. Merck Non-Melanoma Skin Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. Almirall Corporate Information, Location and Competitors
Table 60. Almirall Non-Melanoma Skin Cancer Major Business
Table 61. Almirall Non-Melanoma Skin Cancer Total Revenue (USD Million) (2017-2018)
Table 62. Almirall SWOT Analysis
Table 63. Almirall Non-Melanoma Skin Cancer Product and Solutions
Table 64. Almirall Non-Melanoma Skin Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 65. Ion Beam Applications Corporate Information, Location and Competitors
Table 66. Ion Beam Applications Non-Melanoma Skin Cancer Major Business
Table 67. Ion Beam Applications Non-Melanoma Skin Cancer Total Revenue (USD Million) (2017-2018)
Table 68. Ion Beam Applications SWOT Analysis
Table 69. Ion Beam Applications Non-Melanoma Skin Cancer Product and Solutions
Table 70. Ion Beam Applications Non-Melanoma Skin Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 71. Varian Medical Systems Corporate Information, Location and Competitors
Table 72. Varian Medical Systems Non-Melanoma Skin Cancer Major Business
Table 73. Varian Medical Systems Non-Melanoma Skin Cancer Total Revenue (USD Million) (2017-2018)
Table 74. Varian Medical Systems SWOT Analysis
Table 75. Varian Medical Systems Non-Melanoma Skin Cancer Product and Solutions
Table 76. Varian Medical Systems Non-Melanoma Skin Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 77. Accuray Corporate Information, Location and Competitors
Table 78. Accuray Non-Melanoma Skin Cancer Major Business
Table 79. Accuray Non-Melanoma Skin Cancer Total Revenue (USD Million) (2017-2018)
Table 80. Accuray SWOT Analysis
Table 81. Accuray Non-Melanoma Skin Cancer Product and Solutions
Table 82. Accuray Non-Melanoma Skin Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 83. Sensus Healthcare Corporate Information, Location and Competitors
Table 84. Sensus Healthcare Non-Melanoma Skin Cancer Major Business
Table 85. Sensus Healthcare Non-Melanoma Skin Cancer Total Revenue (USD Million) (2017-2018)
Table 86. Sensus Healthcare SWOT Analysis
Table 87. Sensus Healthcare Non-Melanoma Skin Cancer Product and Solutions
Table 88. Sensus Healthcare Non-Melanoma Skin Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 89. iCAD Corporate Information, Location and Competitors
Table 90. iCAD Non-Melanoma Skin Cancer Major Business
Table 91. iCAD Non-Melanoma Skin Cancer Total Revenue (USD Million) (2017-2018)
Table 92. iCAD SWOT Analysis
Table 93. iCAD Non-Melanoma Skin Cancer Product and Solutions
Table 94. iCAD Non-Melanoma Skin Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 95. Global Non-Melanoma Skin Cancer Revenue (Million USD) by Players (2015-2020)
Table 96. Global Non-Melanoma Skin Cancer Revenue Share by Players (2015-2020)
Table 97. Global Non-Melanoma Skin Cancer Revenue (Million USD) by Regions (2015-2020)
Table 98. Global Non-Melanoma Skin Cancer Revenue Market Share by Regions (2015-2020)
Table 99. North America Non-Melanoma Skin Cancer Revenue by Countries (2015-2020)
Table 100. North America Non-Melanoma Skin Cancer Revenue Market Share by Countries (2015-2020)
Table 101. Europe Non-Melanoma Skin Cancer Revenue (Million USD) by Countries (2015-2020)
Table 102. Asia-Pacific Non-Melanoma Skin Cancer Revenue (Million USD) by Countries (2015-2020)
Table 103. South America Non-Melanoma Skin Cancer Revenue by Countries (2015-2020)
Table 104. South America Non-Melanoma Skin Cancer Revenue Market Share by Countries (2015-2020)
Table 105. Middle East and Africa Non-Melanoma Skin Cancer Revenue (Million USD) by Countries (2015-2020)
Table 106. Middle East and Africa Non-Melanoma Skin Cancer Revenue Market Share by Countries (2015-2020)
Table 107. Global Non-Melanoma Skin Cancer Revenue (Million USD) by Type (2015-2020)
Table 108. Global Non-Melanoma Skin Cancer Revenue Share by Type (2015-2020)
Table 109. Global Non-Melanoma Skin Cancer Revenue Forecast by Type (2021-2025)
Table 110. Global Non-Melanoma Skin Cancer Revenue by Application (2015-2020)
Table 111. Global Non-Melanoma Skin Cancer Revenue Share by Application (2015-2020)
Table 112. Global Non-Melanoma Skin Cancer Revenue Forecast by Application (2021-2025)
Table 113. Global Non-Melanoma Skin Cancer Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Non-Melanoma Skin Cancer Picture
Figure 2. Global Non-Melanoma Skin Cancer Revenue Market Share by Type in 2019
Figure 3. Chemotherapy Picture
Figure 4. Radiation Therapy Picture
Figure 5. Photodynamic Therapy Picture
Figure 6. Non-Melanoma Skin Cancer Revenue Market Share by Application in 2019
Figure 7. Hospitals Picture
Figure 8. Clinics Picture
Figure 9. Ambulatory Surgical Centers Picture
Figure 10. Others Picture
Figure 11. Global Non-Melanoma Skin Cancer Revenue (USD Million) and Growth Rate (2015-2025)
Figure 12. North America Non-Melanoma Skin Cancer Revenue (Million USD) and Growth Rate (2015-2025)
Figure 13. Europe Non-Melanoma Skin Cancer Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Asia-Pacific Non-Melanoma Skin Cancer Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. South America Non-Melanoma Skin Cancer Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Middle East and Africa Non-Melanoma Skin Cancer Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Global Non-Melanoma Skin Cancer Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Global Non-Melanoma Skin Cancer Revenue Share by Players in 2019
Figure 19. Global Top 5 Players Non-Melanoma Skin Cancer Revenue Market Share in 2019
Figure 20. Global Top 10 Players Non-Melanoma Skin Cancer Revenue Market Share in 2019
Figure 21. Key Players Market Share Trend
Figure 22. Global Non-Melanoma Skin Cancer Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 23. Global Non-Melanoma Skin Cancer Revenue Market Share by Regions (2015-2020)
Figure 24. Global Non-Melanoma Skin Cancer Revenue Market Share by Regions in 2018
Figure 25. North America Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
Figure 26. Europe Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
Figure 27. Asia-Pacific Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
Figure 28. South America Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
Figure 29. Middle East and Africa Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
Figure 30. North America Non-Melanoma Skin Cancer Revenue Market Share by Countries (2015-2020)
Figure 31. North America Non-Melanoma Skin Cancer Revenue Market Share by Countries in 2019
Figure 32. USA Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
Figure 33. Canada Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
Figure 34. Mexico Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
Figure 35. Europe Non-Melanoma Skin Cancer Revenue Market Share by Countries (2015-2020)
Figure 36. Europe Non-Melanoma Skin Cancer Revenue Market Share by Countries in 2019
Figure 37. Germany Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
Figure 38. UK Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
Figure 39. France Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
Figure 40. Russia Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
Figure 41. Italy Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
Figure 42. Asia-Pacific Non-Melanoma Skin Cancer Revenue Market Share by Countries (2015-2020)
Figure 43. Asia-Pacific Non-Melanoma Skin Cancer Revenue Market Share by Countries in 2019
Figure 44. China Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
Figure 45. Japan Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
Figure 46. Korea Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
Figure 47. India Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
Figure 48. Southeast Asia Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
Figure 49. South America Non-Melanoma Skin Cancer Revenue Market Share by Countries (2015-2020)
Figure 50. South America Non-Melanoma Skin Cancer Revenue Market Share by Countries in 2019
Figure 51. Brazil Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
Figure 52. Argentina Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
Figure 53. Middle East and Africa Non-Melanoma Skin Cancer Revenue Market Share by Countries (2015-2020)
Figure 54. Middle East and Africa Non-Melanoma Skin Cancer Revenue Market Share by Countries in 2019
Figure 55. Saudi Arabia Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
Figure 56. UAE Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
Figure 57. Egypt Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
Figure 58. South Africa Non-Melanoma Skin Cancer Revenue and Growth Rate (2015-2020)
Figure 59. Global Non-Melanoma Skin Cancer Revenue Share by Type (2015-2020)
Figure 60. Global Non-Melanoma Skin Cancer Revenue Share by Type in 2019
Figure 61. Global Non-Melanoma Skin Cancer Market Share Forecast by Type (2021-2025)
Figure 62. Global Chemotherapy Revenue Growth Rate (2015-2020)
Figure 63. Global Radiation Therapy Revenue Growth Rate (2015-2020)
Figure 64. Global Photodynamic Therapy Revenue Growth Rate (2015-2020)
Figure 65. Global Non-Melanoma Skin Cancer Revenue Share by Application (2015-2020)
Figure 66. Global Non-Melanoma Skin Cancer Revenue Share by Application in 2019
Figure 67. Global Non-Melanoma Skin Cancer Market Share Forecast by Application (2021-2025)
Figure 68. Global Hospitals Revenue Growth Rate (2015-2020)
Figure 69. Global Clinics Revenue Growth Rate (2015-2020)
Figure 70. Global Ambulatory Surgical Centers Revenue Growth Rate (2015-2020)
Figure 71. Global Others Revenue Growth Rate (2015-2020)
Figure 72. Global Non-Melanoma Skin Cancer Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 73. Global Non-Melanoma Skin Cancer Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 74. Global Non-Melanoma Skin Cancer Revenue Market Share Forecast by Regions (2021-2025)
Figure 75. North America Non-Melanoma Skin Cancer Revenue Market Forecast (2021-2025)
Figure 76. Europe Non-Melanoma Skin Cancer Revenue Market Forecast (2021-2025)
Figure 77. Asia-Pacific Non-Melanoma Skin Cancer Revenue Market Forecast (2021-2025)
Figure 78. South America Non-Melanoma Skin Cancer Revenue Market Forecast (2021-2025)
Figure 79. Middle East and Africa Non-Melanoma Skin Cancer Revenue Market Forecast (2021-2025)
Figure 80. Sales Channel: Direct Channel vs Indirect Channel
非黒色腫皮膚がん治療の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Non-Melanoma Skin Cancer Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Non-Melano…- 黒色腫がんの世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Melanoma Cancer market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Melanoma Cancer market report…
- 皮膚がん診断・治療の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Skin Cancer Diagnosis and Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Skin C…
- 基底細胞皮膚癌治療の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The Basal Cell Skin Cancer Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain op…
- 皮膚がん治療の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Skin Cancer Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Skin Cancer Therapeu…